Combined neuroendocrine differentiation and androgen receptor hyperactivity in MAP37 and CHD1 null prostate cancer

被引：0
|
作者：
Rider, Leah C.
Rodrigues, Lindsey U.
Karimpour-Fard, Anis
Romero, Lina
Gillette, Claire
Costello, James C.
Cramer, Scott D.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1580
引用
收藏
页数：2
相关论文
共 42 条
  • [41] ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NAïVE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY
    Shore, Neal
    Lang, Joshua M.
    Geynisman, Daniel M.
    Stewart, Tyler F.
    Gao, Xin
    Appleman, Leonard J.
    Dreicer, Robert
    Dorff, Tanya
    Berghorn, Elmer
    Duperret, Elizabeth
    Lu, Haolan
    Chan, Edward
    Garmezy, Benjamin
    Petrylak, Daniel P.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E227 - E227
  • [42] WNT1-inducible signaling pathway protein 1 activation through C-X-C motif chemokine ligand 5/C-X-C chemokine receptor type 2/leukemia inhibitory factor/leukemia inhibitory factor receptor signaling promotes immunosuppression and neuroendocrine differentiation in prostate cancer
    Tsui, Ke Hung
    Liu, Chien-Liang
    Yeh, Hsiu-Lien
    Liu, Ming-Kun
    Li, Chien-Hsiu
    Chen, Wei-Hao
    Jiang, Kuo-Ching
    Li, Han-Ru
    Dung, Phan Vu Thuy
    Hsiao, Michael
    Abou-Kheir, Wassim
    Liu, Yen-Nien
    ISCIENCE, 2024, 27 (08)
12345